Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 12/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.36 |
| ▸ | KLK1 | P06870 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6630676 | 0.71 | HTT (0.35) | F2R | |
| SCHEMBL6630767 | 0.70 | F2R (0.46) | F2R | |
| SCHEMBL13945250 | 0.69 | F2R (0.44) | F2RF2KLKB1KLK1 | |
| SCHEMBL12340155 | 0.68 | F2R (0.67) | F2RF2 | |
| SCHEMBL12340165 | 0.67 | F2R (0.49) | F2RF2KLKB1 | |
| SCHEMBL13945253 | 0.66 | F2R (0.74) | F2RF2 | |
| SCHEMBL12340177 | 0.65 | F2R (0.63) | F2RF2 | |
| SCHEMBL12340158 | 0.64 | F2R (0.65) | F2RF2 | |
| SCHEMBL4263176 | 0.63 | F2R (0.85) | F2RF2 | |
| SCHEMBL30589701 | 0.63 | F2R (0.85) | F2RF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6740657-B2 | FOR EXAMPLE, N3-CYCLOPROPYL-7-((2,6-DICHLOROPHENYL)METHYL)-9-((DIMETHYLAMINO)METHYL)-7H -PYRROLO(3,2-F) QUINAZOLINE-1,3-DIAMI NE; TREATING CARDIOVASCULAR DISORDERS, RESTENOSIS, THROMBOSIS, AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-05-25 | — | — | US | claimed |
| EP-1370560-B1 | AMINOMETHYL-PYRROLOQUINAZOLINE COMPOUNDS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2004-11-10 | — | — | EP | disclosed |
| US-6740657-B2 | FOR EXAMPLE, N3-CYCLOPROPYL-7-((2,6-DICHLOROPHENYL)METHYL)-9-((DIMETHYLAMINO)METHYL)-7H -PYRROLO(3,2-F) QUINAZOLINE-1,3-DIAMI NE; TREATING CARDIOVASCULAR DISORDERS, RESTENOSIS, THROMBOSIS, AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-05-25 | — | — | US | disclosed |
| US-20020160963-A1 | Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160963-A1 | Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists | F2R, F2RL1, F2RL3 | F2R 1/4885F2 16/4885KLKB1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.